Vaccines and immunotherapeutics for the treatment of malignant disease

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Aldrich, Joel F ^a   Lowe, Devin B ^a   Shearer, Michael H ^a   Winn, Richard E ^a   Jumper, Cynthia A ^a   Kennedy, Ronald C ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BACTERIAL VECTOR; BEVACIZUMAB; CANCER VACCINE; CD33 ANTIGEN; CD52 ANTIGEN; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; LATENT MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; PANITUMUMAB; PLASMID DNA; PROVENGE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; VASCULOTROPIN; WART VIRUS VACCINE; CYTOKINE; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG APPROVAL; EPSTEIN BARR VIRUS; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HELICOBACTER PYLORI; HEPATITIS C VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT MESOTHELIOMA; MELANOMA; NATURAL KILLER CELL; OVARY CANCER; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; STOMACH CANCER; TH1 CELL; TH17 CELL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR CELL; TUMOR IMMUNITY; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; VIRUS RECOMBINANT; ANIMAL; DOG; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; DOGS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS;

EID: 78349294207     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/697158     Document Type: Review

References (92)

1. Burnet M., Cancer: a biological approach British Medical Journal 1957 1 841 847
2. Burnet F. M., The concept of immunological surveillance Progress in Experimental Tumor Research 1970 13 1 27
3. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111
4. Frisch M., Biggar R. J., Engels E. A., Goedert J. J., Association of cancer with AIDS-related immunosuppression in adults Journal of the American Medical Association 2001 285 13 1736 1745
5. Gutierrez-Dalmau A., Campistol J. M., Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 2007 67 8 1167 1198
6. Waldmann T. A., Immunotherapy: past, present and future Nature Medicine 2003 9 3 269 277
7. Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8372 8377
8. Jacob J. B., Kong Y. C., Nalbantoglu I., Snower D. P., Wei W. Z., Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity Journal of Immunology 2009 182 9 5873 5881
9. Carter P. J., Potent antibody therapeutics by design Nature Reviews Immunology 2006 6 5 343 357
10. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148
11. Kim R., Emi M., Tanabe K., Cancer immunoediting from immune surveillance to immune escape Immunology 2007 121 1 1 14
12. Lu S., Heterologous prime-boost vaccination Current Opinion in Immunology 2009 21 3 346 351
13. Pise-Masison C. A., Choi K.-S., Radonovich M., Dittmer J., Kim S.-J., Brady J. N., Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein Journal of Virology 1998 72 2 1165 1170
14. Lane D. P., Crawford L. V., T antigen is bound to a host protein in SV40 transformed cells Nature 1979 278 5701 261 263
15. Reuschenbach M., von Knebel Doeberitz M., Wentzensen N., A systematic review of humoral immune responses against tumor antigens Cancer Immunology, Immunotherapy 2009 58 10 1535 1544
16. Deleo A. B., p53-based immunotherapy of cancer Critical Reviews in Immunology 1997 18 1-2 29 35
17. Lowe D. B., Shearer M. H., Jumper C. A., Kennedy R. C., Towards progress on DNA vaccines for cancer Cellular and Molecular Life Sciences 2007 64 18 2391 2403
18. Duraiswamy J., Sherritt M., Thomson S., Tellam J., Cooper L., Connolly G., Bharadwaj M., Khanna R., Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma Blood 2003 101 8 3150 3156
19. Lowe D. B., Shearer M. H., Tarbox J. A., Kang H. S., Jumper C. A., Bright R. K., Kennedy R. C., In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization Virology 2005 332 1 28 37
20. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 1991 254 5038 1643 1647
21. Novellino L., Castelli C., Parmiani G., A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunology, Immunotherapy 2005 54 3 187 207
22. Haupt K., Roggendorf M., Mann K., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy Experimental Biology and Medicine 2002 227 4 227 237
23. Wolff J. A., Malone R. W., Williams P., Chong W., Acsadi G., Jani A., Felgner P. L., Direct gene transfer into mouse muscle in vivo Science 1990 247 4949 1465 1468
24. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A., Heterologous protection against influenza by injection of DNA encoding a viral protein Science 1993 259 5102 1745 1749 (Pubitemid 23114660)
25. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.-C., Sandstrm E., Wahren B., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients The Lancet 1998 351 9112 1320 1325
26. Wang R., Doolan D. L., Le T. P., Hedstrom R. C., Coonan K. M., Charoenvit Y., Jones T. R., Hobart P., Margalith M., Ng J., Weiss W. R., Sedegah M., De Taisne C., Norman J. A., Hoffman S. L., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine Science 1998 282 5388 476 480
27. MacGregor R. R., Boyer J. D., Ugen K. E., Lacy K. E., Gluckman S. J., Bagarazzi M. L., Chattergoon M. A., Baine Y., Higgins T. J., Ciccarelli R. B., Coney L. R., Ginsberg R. S., Weiner D. B., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response Journal of Infectious Diseases 1998 178 1 92 100
28. Bergman P. J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A. E., Segal N., Gregor P., Engelhorn M., Riviere I., Houghton A. N., Wolchok J. D., Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial Clinical Cancer Research 2003 9 4 1284 1290
29. Liao J. C., Gregor P., Wolchok J. D., Orlandi F., Craft D., Leung C., Houghton A. N., Bergman P. J., Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma Cancer Immunity 2006 6, article 8
30. Prud'homme G. J., DNA vaccination against tumors Journal of Gene Medicine 2005 7 1 3 17
31. Van Damme P., Cramm M., Safary A., Vandepapeliere P., Meheus A., Heat stability of a recombinant DNA hepatitis B vaccine Vaccine 1992 10 6 366 367
32. Song K., Chang Y., Prud'homme G. J., Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer Gene Therapy 2000 7 6 481 492
33. Maecker H. T., Umetsu D. T., DeKruyff R. H., Levy S., DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin Vaccine 1997 15 15 1687 1696
34. Rohrbach F., Weth R., Kursar M., Sloots A., Mittrcker H.-W., Wels W. S., Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity Journal of Immunology 2005 174 9 5481 5489
35. Charo J., Ciupitu A.-M. T., De Prville A. L. C., Trivedi P., Klein G., Hinkula J., Kiessling R., A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene Journal of Immunology 1999 163 11 5913 5919
36. Buchan S., Grnevik E., Mathiesen I., King C. A., Stevenson F. K., Rice J., Electroporation as a prime/boost strategy for naked DNA vaccination against a tumor antigen Journal of Immunology 2005 174 10 6292 6298
37. Brve A., Hallengrd D., Gudmundsdotter L., Stout R., Walters R., Wahren B., Hallermalm K., Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen Vaccine 2009 27 28 3692 3696
38. Radcliffe J. N., Roddick J. S., Friedmann P. S., Stevenson F. K., Thirdborough S. M., Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells Journal of Immunology 2006 177 10 6626 6633
39. Todorova K., Ignatova I., Tchakarov S., Altankova I., Zoubak S., Kyurkchiev S., Mincheff M., Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded Cancer Immunity 2005 5, article 1
40. Palucka A. K., Ueno H., Fay J. W., Banchereau J., Taming cancer by inducing immunity via dendritic cells Immunological Reviews 2007 220 1 129 150
41. Higano C. S., Schellhammer P. F., Small E. J., Burch P. A., Nemunaitis J., Yuh L., Provost N., Frohlich M. W., Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 2009 115 16 3670 3679
42. Rock K. L., Shen L., Cross-presentation: underlying mechanisms and role in immune surveillance Immunological Reviews 2005 207 166 183
43. Faure F., Mantegazza A., Sadaka C., Sedlik C., Jotereau F., Amigorena S., Long-lasting cross-presentation of tumor antigen in human DC European Journal of Immunology 2009 39 2 380 390
44. Klinman D. M., Immunotherapeutic uses of CpG oligodeoxynucleotides Nature Reviews Immunology 2004 4 4 249 258
45. Krieg A. M., CpG motifs in bacterial DNA and their immune effects Annual Review of Immunology 2002 20 709 760
46. Yang Y., Huang C.-T., Huang X., Pardoll D. M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance Nature Immunology 2004 5 5 508 515
47. Mossoba M. E., Walia J. S., Rasaiah V. I., Buxhoeveden N., Head R., Ying C., Foley J. E., Bramson J. L., Fowler D. H., Medin J. A., Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2 Molecular Therapy 2008 16 3 607 617
48. He Y., Zhang J., Mi Z., Robbins P., Falo L. D. Jr., Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity Journal of Immunology 2005 174 6 3808 3817
49. Metharom P., Ellem K. A., Wei M. Q., Gene transfer to dendritic cells induced a protective immunity against melanoma Cellular Molecular Immunology 2005 2 4 281 288
50. Chua B. Y., Eriksson E. M., Brown L. E., Zeng W., Gowans E. J., Torresi J., Jackson D. C., A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection Vaccine 2008 26 37 4866 4875
51. Tasaki K., Yoshida Y., Maeda T., Miyauchi M., Kawamura K., Takenaga K., Yamamoto H., Kouzu T., Asano T., Ochiai T., Sakiyama S., Tagawa M., Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells Cancer Gene Therapy 2000 7 2 247 254
52. Tasaki K., Yoshida Y., Miyauchi M., Maeda T., Takenaga K., Kouzu T., Asano T., Ochiai T., Sakiyamna S., Tagawa M., Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts Cancer Gene Therapy 2000 7 2 255 261
53. Ugai S.-I., Shimozato O., Kawamura K., Wang Y.-Q., Yamaguchi T., Saisho H., Sakiyama S., Tagawa M., Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts Cancer Gene Therapy 2003 10 3 187 192 (Pubitemid 36348679)
54. Wang Y.-Q., Ugai S.-I., Shimozato O., Yu L., Kawamura K., Yamamoto H., Yamaguchi T., Saisho H., Tagawa M., Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells International Journal of Cancer 2003 105 6 820 824
55. Liu L., Shan B., Feng Y., Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus Cellular Immunology 2009 258 2 181 187
56. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., Tagawa M., Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals International Journal of Cancer 2005 115 3 437 442
57. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T. H., Chang A., Coukos G., Liu R., Zou W., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments Blood 2009 114 6 1141 1149
58. Langrish C. L., Chen Y., Blumenschein W. M., Mattson J., Basham B., Sedgwick J. D., McClanahan T., Kastelein R. A., Cua D. J., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation Journal of Experimental Medicine 2005 201 2 233 240
59. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., Weaver C. T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nature Immunology 2005 6 11 1123 1132
60. Park H., Li Z., Yang X. O., Chang S. H., Nurieva R., Wang Y.-H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nature Immunology 2005 6 11 1133 1141
61. Bettelli E., Carrier Y., Gao W., Korn T., Strom T. B., Oukka M., Weiner H. L., Kuchroo V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 2006 441 7090 235 238
62. Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 Journal of Clinical Oncology 1999 17 7 2105 2116
63. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 Journal of the American Medical Association 1994 271 12 907 913
64. Kochenderfer J. N., Chien C. D., Simpson J. L., Gress R. E., Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides Clinical Immunology 2007 124 2 119 130
65. Lenardo M. J., Fas and the art of lymphocyte maintenance Journal of Experimental Medicine 1996 183 3 721 724
66. Dranoff G., GM-CSF-based cancer vaccines Immunological Reviews 2002 188 147 154
67. Eriksen K. W., Sndergaard H., Woetmann A., Krejsgaard T., Skak K., Geisler C., Wasik M. A., dum N., The combination of IL-21 and IFN- boosts STAT3 activation, cytotoxicity and experimental tumor therapy Molecular Immunology 2009 46 5 812 820
68. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 Journal of the National Cancer Institute 1994 86 15 1159 1166
69. Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D., Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proceedings of the National Academy of Sciences of the United States of America 2002 99 25 16168 16173
70. Padhani A. R., Ollivier M. D., The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists The British Journal of Radiology 2001 74 983 986
71. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357
72. Melief C. J. M., Cancer immunotherapy by dendritic cells Immunity 2008 29 3 372 383
73. Willemsen R. A., Debets R., Chames P., Bolhuis R. L. H., Genetic engineering of T cell specificity for immunotherapy of cancer Human Immunology 2003 64 1 56 68
74. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129
75. Parkhurst M. R., Salgaller M. L., Southwood S., Robbins P. F., Sette A., Rosenberg S. A., Kawakami Y., Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201-binding residues Journal of Immunology 1996 157 6 2539 2548
76. Ehrlich P., Himmelweir B., On immunity with special reference to cell life: Croonian lecture The Collected Papers of Paul Ehrlich, Vol. II: Immunology and Cancer Research 1956 London, UK Pergammon 148 192
77. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J. V., Fc receptors are required in passive and active immunity to melanoma Proceedings of the National Academy of Sciences of the United States of America 1998 95 2 652 656
78. Kennedy R. C., Shearer M. H., Lowe D. B., Jumper C. A., Chiriva-Internati M., Bright R. K., Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity Cancer Immunology, Immunotherapy 2004 53 11 987 994
79. Nahta R., Esteva F. J., Trastuzumab: triumphs and tribulations Oncogene 2007 26 25 3637 3643
80. Smith M. R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 2003 22 47 7359 7368
81. Phan G. Q., Weber J. S., Sondak V. K., CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues Annals of Surgical Oncology 2008 15 11 3014 3021
82. Hernndez J., Ko A., Sherman L. A., CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen Journal of Immunology 2001 166 6 3908 3914
83. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor ) monoclonal antibody Cancer Research 1999 59 13 3128 3133
84. Zou W., Regulatory T cells, tumour immunity and immunotherapy Nature Reviews Immunology 2006 6 4 295 307
85. Zhou G., Levitsky H. I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance Journal of Immunology 2007 178 4 2155 2162
86. Jonuleit H., Schmitt E., The regulator T cell family: distinct subsets and their Interrelations Journal of Immunology 2003 171 12 6323 6327
87. Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A., A humanized antibody that binds to the interleukin 2 receptor Proceedings of the National Academy of Sciences of the United States of America 1989 86 24 10029 10033
88. De Visser K. E., Eichten A., Coussens L. M., Paradoxical roles of the immune system during cancer development Nature Reviews Cancer 2006 6 1 24 37
89. Shevach E. M., Mechanisms of Foxp3+ T regulatory cell-mediated suppression Immunity 2009 30 5 636 645
90. Sakaguchi S., Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses Annual Review of Immunology 2004 22 531 562
91. Hsu D. S., Kim M. K., Balakumaran B. S., Immune signatures predict prognosis in localized cancer Cancer Investigation 2010 28 765 773
92. Dannenberg A. J., Subbaramaiah K., Targeting cyclooxygenase-2 in human neoplasia: rationale and promise Cancer Cell 2003 4 6 431 436